# Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT

> **NCT06222489** · PHASE2 · RECRUITING · sponsor: **The Netherlands Cancer Institute** · enrollment: 16 (estimated)

## Conditions studied

- Non-Small Cell Lung Carcinoma
- Advanced Non-Small Cell Squamous Lung Cancer
- EGFR Gene Mutation

## Interventions

- **DRUG:** 89Zr-Patritumab deruxtecan

## Key facts

- **NCT ID:** NCT06222489
- **Lead sponsor:** The Netherlands Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-03
- **Primary completion:** 2027-05-01
- **Final completion:** 2028-05-01
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2025-03-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06222489

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06222489, "Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06222489. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*